{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-210664","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.886181+00:00","generated_at":"2026-05-14T21:56:40.128499+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aardvark Q1 net loss $21.6M; ARD-101/ARD-201 programs on voluntary pause","bullets":["Net loss of $21.6M for Q1 2026 vs. $9.3M for Q1 2025, driven by higher R&D expenses.","Cash, cash equivalents and ST investments at $91.2M (down from $110.0M Dec 31, 2025); runway into mid-2027.","R&D expenses $16.6M (up $8.8M YoY) due to ARD-101 development and personnel costs.","Voluntary pause on Phase 3 HERO trial and ARD-201 after reversible cardiac signals in a healthy volunteer study.","Company working with FDA and expects to provide program guidance in Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-210664","json":"https://secwatch.observer/filing/0001193125-26-210664.json","markdown":"https://secwatch.observer/filing/0001193125-26-210664.md","text":"https://secwatch.observer/filing/0001193125-26-210664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/ck0001774857-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:56:40.128499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e0a0c8d29575bd0ef2b7d2d438a802f32e741e86","claim":"Aardvark Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $91.2 million, net income net loss of $21.6 million.","evidence_excerpt":"Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001193125-26-213239","ticker":"ARTV","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Artiva reports 71% ACR50 in refractory RA at 6 months, FDA alignment for Phase 3 trial; Q1 net loss $23.5M","event_type":"other_material","sec_items":["2.02","7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-213239","json":"https://secwatch.observer/filing/0001193125-26-213239.json","markdown":"https://secwatch.observer/filing/0001193125-26-213239.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/0001193125-26-213239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160d8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm","comparable_excerpt":"Artiva Biotherapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/0001193125-26-213239-index.htm"}},{"accession":"0001315257-26-000036","ticker":"KOP","company_name":"Koppers Holdings Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Koppers conditionally plans to shut Stickney, IL chemical operations; Q1 adjusted EPS down 19.7%","event_type":"other_material","sec_items":["2.02","2.05","5.02","5.07","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001315257-26-000036","json":"https://secwatch.observer/filing/0001315257-26-000036.json","markdown":"https://secwatch.observer/filing/0001315257-26-000036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1315257/000131525726000036/0001315257-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1315257/000131525726000036/kop-20260507.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm","comparable_excerpt":"McGuireQT@koppers.com Koppers Holdings Inc. 436 Seventh Avenue Pittsburgh, PA 15219-1800 Tel 412 227 2001 www.koppers.com KOPPERS REPORTS FIRST QUARTER 2026 RESULTS • Sales of $455.3 million vs. $456.5 million in Prior Year Quarter • Net income (loss) of $7.1 million vs. $(13.9) million in Prior Year Quarter • Diluted EPS of $0.35 vs. $(0.68) in Prior Year Quarter •","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1315257/000131525726000036/0001315257-26-000036-index.htm"}},{"accession":"0001193125-26-215803","ticker":"LMFA","company_name":"LM FUNDING AMERICA, INC.","filed_at":"2026-05-11T23:59:59+00:00","headline":"LM Funding April Bitcoin production flat at 9.4 BTC; HODL slips to 334.0","event_type":"other_material","sec_items":["2.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215803","json":"https://secwatch.observer/filing/0001193125-26-215803.json","markdown":"https://secwatch.observer/filing/0001193125-26-215803.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640384/000119312526215803/0001193125-26-215803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640384/000119312526215803/lmfa-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm","comparable_excerpt":"LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin treasury and mining company, today announced its preliminary, unaudited Bitcoin mining and operational update for the month ended April 30, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1640384/000119312526215803/0001193125-26-215803-index.htm"}},{"accession":"0001104659-26-068983","ticker":"GMRS","company_name":"GMR Solutions Inc.","filed_at":"2026-06-01T20:45:55+00:00","headline":"GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068983","json":"https://secwatch.observer/filing/0001104659-26-068983.json","markdown":"https://secwatch.observer/filing/0001104659-26-068983.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/gmrs-20260601x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm","comparable_excerpt":"today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm"}},{"accession":"0001628280-26-039474","ticker":"CRDO","company_name":"Credo Technology Group Holding Ltd","filed_at":"2026-06-01T20:08:16+00:00","headline":"Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs","event_type":"earnings","sec_items":["2.02","5.02","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039474","json":"https://secwatch.observer/filing/0001628280-26-039474.json","markdown":"https://secwatch.observer/filing/0001628280-26-039474.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807794/000162828026039474/0001628280-26-039474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807794/000162828026039474/crdo-20260528.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm","comparable_excerpt":"On June 1, 2026, Credo Technology Group Holding Ltd (the \"Company\") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1807794/000162828026039474/0001628280-26-039474-index.htm"}},{"accession":"0001628280-26-039379","ticker":null,"company_name":"DAVEY TREE EXPERT CO","filed_at":"2026-06-01T17:50:11+00:00","headline":"Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039379","json":"https://secwatch.observer/filing/0001628280-26-039379.json","markdown":"https://secwatch.observer/filing/0001628280-26-039379.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/0001628280-26-039379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/davey-20260528.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm","comparable_excerpt":"Exchange Act, unless such subsequent filing specifically references this Form 8-K. \n\n--- EX-99.1 (EX-99.1) ---\n\nTo Our Shareholders, The Company’s first quarter 2026 revenue of $435.8 million increased slightly from the record first quarter 2025 revenue by $1.0 million, or 0.2%. This growth was driven by consistent demand in the Utility segment, where revenue","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/0001628280-26-039379-index.htm"}},{"accession":"0000029332-26-000027","ticker":"DXYN","company_name":"DIXIE GROUP INC","filed_at":"2026-05-11T23:59:59+00:00","headline":"Dixie Group Q1 2026 net income $1.4M vs loss of $1.6M YoY; sales down 5.7%","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000029332-26-000027","json":"https://secwatch.observer/filing/0000029332-26-000027.json","markdown":"https://secwatch.observer/filing/0000029332-26-000027.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/0000029332-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/dxyn-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm","comparable_excerpt":"2026) -- The Dixie Group, Inc. (OTCQB: DXYN) today reported financial results for the quarter ended March 28, 2026. For the first quarter of 2026, the Company had net sales of $59,380,000 as compared to $62,990,000 in the same quarter of 2025. The Company had an operating income of $3,264,000 in the first quarter of 2026 compared to an operating income of $11,000","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/0000029332-26-000027-index.htm"}},{"accession":"0001043000-26-000016","ticker":"SNDA","company_name":"SONIDA SENIOR LIVING, INC.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Sonida Senior Living reports Q1 net loss of $41.2M; revenue up 37% on CHP acquisition","event_type":"earnings","sec_items":["2.02","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001043000-26-000016","json":"https://secwatch.observer/filing/0001043000-26-000016.json","markdown":"https://secwatch.observer/filing/0001043000-26-000016.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/snda-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm","comparable_excerpt":"Sonida Senior Living Announces First Quarter 2026 Results DALLAS, Texas – May 11, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}